Literature DB >> 35972545

In vitro interaction of polyethylene glycol-block-poly(D,L-lactide) nanocapsule devices with host cardiomyoblasts and Trypanosoma cruzi-infective forms.

Raoni Pais Siqueira1,2, Matheus Marques Milagre3, Maria Alice de Oliveira4,3, Renata Tupinambá Branquinho3, Fernanda Karoline Vieira Torchelsen3, Marta de Lana3, Marina Guimarães Carvalho Machado4,3, Margareth Spangler Andrade5, Maria Terezinha Bahia6, Vanessa Carla Furtado Mosqueira7,8.   

Abstract

Chagas disease, caused by the protozoan Trypanosoma cruzi, is an important public health problem in Latin America. Nanoencapsulation of anti-T. cruzi drugs has significantly improved their efficacy and reduced cardiotoxicity. Thus, we investigated the in vitro interaction of polyethylene glycol-block-poly(D,L-lactide) nanocapsules (PEG-PLA) with trypomastigotes and with intracellular amastigotes of the Y strain in cardiomyoblasts, which are the infective forms of T. cruzi, using fluorescence and confocal microscopy. Fluorescently labeled nanocapsules (NCs) were internalized by non-infected H9c2 cells toward the perinuclear region. The NCs did not induce significant cytotoxicity in the H9c2 cells, even at the highest concentrations and interacted equally with infected and non-infected cells. In infected cardiomyocytes, NCs were distributed in the cytoplasm and located near intracellular amastigote forms. PEG-PLA NCs and trypomastigote form interactions also occurred. Altogether, this study contributes to the development of engineered polymeric nanocarriers as a platform to encapsulate drugs and to improve their uptake by different intra- and extracellular forms of T. cruzi, paving the way to find new therapeutic strategies to fight the causative agent of Chagas disease.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Cardiomyoblast; Cell uptake; Nanocapsules; Polyethylene glycol-block-poly(D,L-lactide); Trypanosoma cruzi

Mesh:

Substances:

Year:  2022        PMID: 35972545     DOI: 10.1007/s00436-022-07618-0

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.383


  23 in total

Review 1.  Therapeutical approaches under investigation for treatment of Chagas disease.

Authors:  Maria Terezinha Bahia; Lívia de Figueiredo Diniz; Vanessa Carla Furtado Mosqueira
Journal:  Expert Opin Investig Drugs       Date:  2014-05-26       Impact factor: 6.206

Review 2.  Nanopharmaceuticals as a solution to neglected diseases: Is it possible?

Authors:  German A Islan; Marcela Durán; Maximiliano L Cacicedo; Gerson Nakazato; Renata K T Kobayashi; Diego S T Martinez; Guillermo R Castro; Nelson Durán
Journal:  Acta Trop       Date:  2017-02-21       Impact factor: 3.112

3.  Efficacy of Lychnopholide Polymeric Nanocapsules after Oral and Intravenous Administration in Murine Experimental Chagas Disease.

Authors:  Carlos Geraldo Campos de Mello; Renata Tupinambá Branquinho; Maykon Tavares Oliveira; Matheus Marques Milagre; Dênia Antunes Saúde-Guimarães; Vanessa Carla Furtado Mosqueira; Marta de Lana
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

4.  Sesquiterpene lactone in nanostructured parenteral dosage form is efficacious in experimental Chagas disease.

Authors:  Renata Tupinambá Branquinho; Vanessa Carla Furtado Mosqueira; Jaquelline Carla Valamiel de Oliveira-Silva; Marianne Rocha Simões-Silva; Dênia Antunes Saúde-Guimarães; Marta de Lana
Journal:  Antimicrob Agents Chemother       Date:  2014-01-21       Impact factor: 5.191

5.  Clathrin coated pit dependent pathway for Trypanosoma cruzi internalization into host cells.

Authors:  Emile Barrias; Lissa Reignault; Técia M U de Carvalho; Wanderley de Souza
Journal:  Acta Trop       Date:  2019-06-14       Impact factor: 3.112

6.  A new tool to ensure the fluorescent dye labeling stability of nanocarriers: a real challenge for fluorescence imaging.

Authors:  Guillaume Bastiat; Christian Oliver Pritz; Clemens Roider; Florian Fouchet; Erwann Lignières; Alexander Jesacher; Rudolf Glueckert; Monika Ritsch-Marte; Anneliese Schrott-Fischer; Patrick Saulnier; Jean-Pierre Benoit
Journal:  J Control Release       Date:  2013-06-19       Impact factor: 9.776

Review 7.  Innovative lead compounds and formulation strategies as newer kinetoplastid therapies.

Authors:  S Espuelas; D Plano; P Nguewa; M Font; J A Palop; J M Irache; C Sanmartín
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

8.  Trypanosoma cruzi: the effect of variations in experimental conditions on the levels of macrophage infection in vitro.

Authors:  T C Araújo-Jorge; E P Sampaio; W De Souza; M de N Meirelles
Journal:  Parasitol Res       Date:  1989       Impact factor: 2.289

Review 9.  The Parasitic Intracellular Lifestyle of Trypanosomatids: Parasitophorous Vacuole Development and Survival.

Authors:  Marina Ferreira Batista; Carlos Alcides Nájera; Isabela Meneghelli; Diana Bahia
Journal:  Front Cell Dev Biol       Date:  2020-06-10

10.  Benznidazole-resistance in Trypanosoma cruzi: evidence that distinct mechanisms can act in concert.

Authors:  Mônica C O Campos; Leonor L Leon; Martin C Taylor; John M Kelly
Journal:  Mol Biochem Parasitol       Date:  2014-01-23       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.